Biological agents, particularly anti-CD20 and TNF-α antagonists, have been considered for refractory JDM cases; however, their efficacy in the context of GI perforation remains a subject of debate and requires further evidence to substantiate their use. Here, TNF is linked to juvenile dermatomyositis.